Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 9/20 | 0.58 |
| ▸ | RXRB | P28702 | 4/20 | 0.51 |
| ▸ | GRN | P28799 | 1/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 5/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4639120 | 1.00 | GRIN2B (0.58) | GRIN2BRXRBGRNSORT1DRD4 | |
| SCHEMBL14142933 | 0.86 | GRIN2B (0.57) | GRIN2BRXRBGRNSORT1DRD4 | |
| SCHEMBL12696580 | 0.84 | GRIN2B (0.54) | GRIN2BRXRBGRNSORT1DRD4 | |
| SCHEMBL2069105 | 0.84 | GRIN2B (0.54) | GRIN2BRXRBGRNSORT1DRD4 | |
| Hydrochloric Acid SCHEMBL27624207 | 0.83 | GRIN2B (0.53) | GRIN2BRXRBDRD4DRD2DRD3 | |
| SCHEMBL1317489 | 0.81 | GRIN2B (0.53) | GRIN2BRXRBGRNSORT1DRD4 | |
| SCHEMBL1317508 | 0.81 | DRD4 (0.55) | GRIN2BRXRBDRD4DRD2DRD3 | |
| SCHEMBL1759419 | 0.80 | DRD4 (0.55) | GRIN2BGRNSORT1DRD4DRD2 | |
| SCHEMBL3521678 | 0.80 | DRD4 (0.57) | GRIN2BDRD4DRD2DRD3CNR2 | |
| SCHEMBL159384 | 0.80 | DRD4 (0.57) | GRIN2BDRD4DRD2DRD3CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2223916-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | Eli Lilly and Company (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-1682523-B1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7423037-B2 | e.g. 1-[1,1'-biphenyl]-2-yl-2-morpholin-2-ylpropan-2-ol; antidepressant, anxiolytic agent, cognition activator | ELI LILLY AND COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1729754-B1 | SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF HOT FLASHES | LILLY CO ELI (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070083046-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-04-12 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
| EP-1729754-A2 | SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF HOT FLASHES, IMPULSE CONTROL DISORDERS AND PERSONALITY CHANGE DUE TO A GENERAL MEDICAL CONDITION | ELI LILLY AND COMPANY (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1682523-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005060949-A2 | SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF HOT FLASHES, IMPULSE CONTROL DISORDERS AND PERSONALITY CHANGE DUE TO A GENERAL MEDICAL CONDITION | ELI LILLY AND COMPANY (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005047272-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070083046-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | SLC6A2, SLC18A2, SLC6A3 | GRIN2B 105/4885RXRB 3112/4885GRN 1771/4885 |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | SLC6A2, SLC6A4, HTR5A | GRIN2B 1107/4885RXRB 3993/4885GRN 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.